Glaukos Q1 record sales $150.6M (+41% YoY); raises FY2026 guidance to $620-635M

GLAUKOS Corp

2026-Q1 EPS reported -$0.34 revenue$150,571,000

Record net sales $150.6M (+41% YoY, +39% constant currency).
U.S. Glaucoma net sales $93.5M (+58% YoY); Glaucoma total $129.3M (+47% YoY).
GAAP net loss ($0.34)/share; non-GAAP net loss ($0.18)/share; operating loss narrowed YoY.
FY2026 net sales guidance raised to $620-635M from prior $600-620M.
Cash $280.5M, no debt; GAAP gross margin ~78%, non-GAAP ~84%.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GLAUKOS Corp reported the first quarter ended March 31, 2026 results: revenue $150.6 million, net income $19.8 million, EPS ($0.34) per diluted share. Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: $150.6 million
Net income: $19.8 million
EPS: ($0.34) per diluted share
Guidance: raised
Result: reported results

Exact text from the filing

of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: • Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. • Glaucoma record net sales of $129.3 million in Q1 2026

View on SEC.gov

1436 earnings releases filed in the last 30 days. Browse all earnings releases →

GLAUKOS Corp filing history →

Source: SEC EDGAR

accession 0001193125-26-191553

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.